These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 24345653)

  • 21. An adipose tissue-independent insulin-sensitizing action of telmisartan: a study in lipodystrophic mice.
    Rong X; Li Y; Ebihara K; Zhao M; Aini W; Kusakabe T; Hirata M; Miyamoto L; Murray M; Nakao K
    J Pharmacol Exp Ther; 2009 Dec; 331(3):1096-103. PubMed ID: 19770292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Telmisartan at 80 mg/day increases high-molecular-weight adiponectin levels and improves insulin resistance in diabetic patients.
    Mori H; Okada Y; Arao T; Nishida K; Tanaka Y
    Adv Ther; 2012 Jul; 29(7):635-44. PubMed ID: 22821644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of telmisartan on insulin resistance and visceral fat distribution in Chinese hypertensive patients with obesity.
    Huang GZ; Tang YH; Wang BY; Zhang B; Hu TJ; Zhang L; Zhang XY; Zhong Y
    Saudi Med J; 2011 Oct; 32(10):1017-21. PubMed ID: 22008920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Physical activity is associated with risk factors for chronic disease across adult women's life cycle.
    Woolf K; Reese CE; Mason MP; Beaird LC; Tudor-Locke C; Vaughan LA
    J Am Diet Assoc; 2008 Jun; 108(6):948-59. PubMed ID: 18502225
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Telmisartan treatment decreases visceral fat accumulation and improves serum levels of adiponectin and vascular inflammation markers in Japanese hypertensive patients.
    Chujo D; Yagi K; Asano A; Muramoto H; Sakai S; Ohnishi A; Shintaku-Kubota M; Mabuchi H; Yamagishi M; Kobayashi J
    Hypertens Res; 2007 Dec; 30(12):1205-10. PubMed ID: 18344626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Telmisartan inhibits vascular dysfunction and inflammation via activation of peroxisome proliferator-activated receptor-γ in subtotal nephrectomized rat.
    Toba H; Tojo C; Wang J; Noda K; Kobara M; Nakata T
    Eur J Pharmacol; 2012 Jun; 685(1-3):91-8. PubMed ID: 22314223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuroendocrine characterization and anorexigenic effects of telmisartan in diet- and glitazone-induced weight gain.
    Aubert G; Burnier M; Dulloo A; Perregaux C; Mazzolai L; Pralong F; Zanchi A
    Metabolism; 2010 Jan; 59(1):25-32. PubMed ID: 19793594
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does it matter how blood pressure is lowered in patients with metabolic risk factors?
    Sharma AM
    J Am Soc Hypertens; 2008; 2(4 Suppl):S23-9. PubMed ID: 20409934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Telmisartan, a dual ARB/partial PPAR-γ agonist, protects myocardium from ischaemic reperfusion injury in experimental diabetes.
    Goyal SN; Bharti S; Bhatia J; Nag TC; Ray R; Arya DS
    Diabetes Obes Metab; 2011 Jun; 13(6):533-41. PubMed ID: 21320264
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Telmisartan increases localization of glucose transporter 4 to the plasma membrane and increases glucose uptake via peroxisome proliferator-activated receptor γ in 3T3-L1 adipocytes.
    Furukawa H; Mawatari K; Koyama K; Yasui S; Morizumi R; Shimohata T; Harada N; Takahashi A; Nakaya Y
    Eur J Pharmacol; 2011 Jun; 660(2-3):485-91. PubMed ID: 21514293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients.
    Fogari R; Zoppi A; Ferrari I; Mugellini A; Preti P; Lazzari P; Derosa G
    Horm Metab Res; 2009 Dec; 41(12):893-8. PubMed ID: 19708000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distinct properties of telmisartan on agonistic activities for peroxisome proliferator-activated receptor γ among clinically used angiotensin II receptor blockers: drug-target interaction analyses.
    Kakuta H; Kurosaki E; Niimi T; Gato K; Kawasaki Y; Suwa A; Honbou K; Yamaguchi T; Okumura H; Sanagi M; Tomura Y; Orita M; Yonemoto T; Masuzaki H
    J Pharmacol Exp Ther; 2014 Apr; 349(1):10-20. PubMed ID: 24424487
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adiponectin elevation by telmisartan ameliorates ischaemic myocardium in Zucker diabetic fatty rats with metabolic syndrome.
    Rinaldi B; Di Filippo C; Capuano A; Donniacuo M; Sodano L; Ferraraccio F; Rossi F; D'Amico M
    Diabetes Obes Metab; 2012 Apr; 14(4):320-8. PubMed ID: 22050607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change.
    Ikejima H; Imanishi T; Tsujioka H; Kuroi A; Kobayashi K; Shiomi M; Muragaki Y; Mochizuki S; Goto M; Yoshida K; Akasaka T
    J Hypertens; 2008 May; 26(5):964-72. PubMed ID: 18398339
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The differential effects of angiotensin II type 1 receptor blockers on microalbuminuria in relation to low-grade inflammation in metabolic hypertensive patients.
    Yano Y; Hoshide S; Ishikawa J; Noguchi C; Tukui D; Takanori H; Tada M; Kanemaru Y; Yano A; Ishikawa S; Shimada K; Kario K
    Am J Hypertens; 2007 May; 20(5):565-72. PubMed ID: 17485023
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor-gamma activation in diabetic mice.
    Iwanami J; Mogi M; Tsukuda K; Min LJ; Sakata A; Jing F; Iwai M; Horiuchi M
    J Hypertens; 2010 Aug; 28(8):1730-7. PubMed ID: 20498620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An Angiotensin II (Ang II) Type 1 Receptor Blocker, Telmisartan, Improves Insulin Resistance in KK-A(y) Diabetic Mice.
    Takasu T; Kakuta H; Sasamata M; Yamagishi S
    Int J Biomed Sci; 2006 Dec; 2(4):333-6. PubMed ID: 23675001
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evolution of peroxisome proliferator-activated receptor agonists.
    Chang F; Jaber LA; Berlie HD; O'Connell MB
    Ann Pharmacother; 2007 Jun; 41(6):973-83. PubMed ID: 17519293
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liver-specific peroxisome proliferator-activated receptor alpha target gene regulation by the angiotensin type 1 receptor blocker telmisartan.
    Clemenz M; Frost N; Schupp M; Caron S; Foryst-Ludwig A; Böhm C; Hartge M; Gust R; Staels B; Unger T; Kintscher U
    Diabetes; 2008 May; 57(5):1405-13. PubMed ID: 18184928
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet.
    Souza-Mello V; Gregório BM; Cardoso-de-Lemos FS; de Carvalho L; Aguila MB; Mandarim-de-Lacerda CA
    Clin Sci (Lond); 2010 Jun; 119(6):239-50. PubMed ID: 20415664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.